Under the dedicated 2025 theme, ‘Immunization for All is Humanly Possible’, the last week of April marks World Immunization Week, a time to recognise the life-saving power of vaccines, especially as we face new health threats as antimicrobial resistance (AMR). Given their commitment to developing life-saving vaccines using a novel technology, and the financial support already received for their life-saving mission by major investors as Boston accelerator CARB-X, today we are spotlighting EIC Accelerator beneficiary Vaxdyn.
Based in Seville (Spain), as recently revealed by el correo de Andalucía, Vaxdyn is one of the Spanish biotechnology companies which is generating major expectations for their vaccine model that could help protect people from infections no longer responding to antibiotics.
The focus: developing vaccines against the most worrisome bacterial pathogens
Instead of relying on traditional vaccine methods, Vaxdyn’s approach involves using proteins from the bacteria’s outer shell to help the body recognize and fight back against infection. This method is designed to work not just against one type of bacteria, but potentially several that share similar resistance traits.
Targeting Klebsiella pneumoniae – the third leading cause of AMR deaths – the company’s lead vaccine, K-VAX, is already advancing through Phase 1A trials, supported by CARB-X and other private investors.
EIC Accelerator awardee since January 2025, the Seville-based company is leading the homonymous EIC K-VAX project, which will support – through the EU’s contribution of €2 494 748,99 – Phase 1B and Phase 2 trials, crucial to determine the final formulation and efficacy of Vaxdyn’s lead vaccine.
The recent support from Boston accelerator CARB-X
Accelerator exclusively dedicated to projects proposing solutions to the growing issue of bacterial resistance to antibiotics, the private North-American organisation CARB-X – funded, among others, by the Bill & Melinda Gates Foundation – represented a major lever for the Seville-based company to reach the first clinical phase of its lead vaccine.
Together with other 99 projects committed to finding alternatives to traditional antibiotics, Vaxdyn was granted $11 million, as well as highly experienced executives and advisors to whom to report about the achievements reached each month.
Looking ahead towards preventing the next global health crisis
Post-trials, Vaxdyn plans to license K-VAX, continuing the development of its second vaccine, P-VAX, for Pseudomonas aeruginosa, infections targeting patients with chronic respiratory conditions.
With drug-resistant infections being already responsible for around 700.000 deaths each year, Vaxdyn’s vaccines could be a major step forward not only in easing the burden on healthcare systems worldwide but also in preventing deadly, drug-resistant infections in people who are most vulnerable, as those with chronic illnesses.
About Vaxdyn
Vaxdyn is dedicated to developing multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Supported by the EIC Accelerator, Vaxdyn is developing safe and effective vaccines against the most worrisome bacterial pathogens.
Learn more about Better Vaxdyn by visiting the Horizon Europe database and the company official website.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.